BEZ235 + Paclitaxel
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inoperable Locally Advanced Breast Cancer
Conditions
Inoperable Locally Advanced Breast Cancer, Metastatic Breast Cancer (MBC)
Trial Timeline
Jan 30, 2012 → May 19, 2014
NCT ID
NCT01495247About BEZ235 + Paclitaxel
BEZ235 + Paclitaxel is a phase 1/2 stage product being developed by Novartis for Inoperable Locally Advanced Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01495247. Target conditions include Inoperable Locally Advanced Breast Cancer, Metastatic Breast Cancer (MBC).
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01495247 | Phase 1/2 | Terminated |
Competing Products
10 competing products in Inoperable Locally Advanced Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 23 |
| Premetrexed (Alimta) + Carboplatin | Eli Lilly | Phase 1 | 33 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 77 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Tomudex | AstraZeneca | Phase 2 | 52 |
| Cisplatin + Gemcitabine + Selumetinib | AstraZeneca | Phase 1 | 33 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 77 |
| Drug (including placebo) | Merck | Phase 1 | 33 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 22 |